fda update on tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy FDA's tirzepatide decision creates uncertainty

Its not as long as Life Extensions one-year policy, however

These findings indicate that semaglutide (Ozempic) provides greater improvements in both HbA1c and weight compared to liraglutide

Lastly, therapeutic interventions targeting the liver-brain axis remain in the early stages, necessitating rigorous clinical trials to establish efficacy and safety

These pharmacodynamic properties create two interaction surfaces with any compound that modulates serotonin or vascular tone: additive serotonergic toxicity and additive blood pressure effects

Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus